Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (1768)

ProteinN (482)

NSP5 (390)

ComplexRdRp (224)

ProteinE (128)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 23401 - 23410 records in total 23753
    records per page




    Structural basis for receptor recognition by the novel coronavirus from Wuhan

    Authors: Jian Shang; Gang Ye; Ke Shi; Yushun Wan; Chuming Luo; Hideki Aihara; Qibin Geng; Ashley Auerbach; Fang Li

    doi:10.21203/rs.2.24749/v1 Date: 2020-02-25 Source: ResearchSquare

    A novel SARS-like coronavirus (2019-nCoV) recently emerged from Wuhan, China and is quickly spreading in humans. A key to tackling this epidemic is to understand the virus’s receptor recognition mechanism, which regulates its infection, pathogenesis, and host range. 2019-nCoV and SARS-CoV MESHD recognize the same host receptor ACE2 HGNC. Here we determined the crystal structure of 2019-nCoV receptor-binding domain (RBD) (engineered to facilitate crystallization) in complex of human ACE2 HGNC.Compared with SARS-CoV MESHD, an ACE2 HGNC-binding ridge in 2019-nCoV RBD takes more compact conformations, causing structural changes at the RBD/ ACE2 HGNC interface. Adaptive to these structural changes, several mutations in 2019-nCoV RBD enhance ACE2 HGNC- binding affinity, contributing to the high infectivity of 2019-CoV. These mutations also reveal the molecular mechanisms of the animal-to-human transmission of 2019-nCoV. Alarmingly, a single N439R mutation in 2019-nCoV RBD further enhances its ACE2 HGNC- binding affinity, indicating possible future evolution of 2019-nCoV in humans. This study sheds light on the epidemiology and evolution of 2019-nCoV, and provides guidance for intervention strategies targeting receptor recognition by 2019-nCoV.

    Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) During Pregnancy: A Case Series

    Authors: Weiyong Liu; Qianli Wang; Qi Zhang; Ling Chen; Junbo Chen; Bo Zhang; Yanjun Lu; Shaoshuai Wang; Liming Xia; Lu Huang; Kai Wang; Lu Liang; Yongli Zhang; Lance Turtle; David Lissauer; Ke Lan; Ling Feng; Hongjie Yu; Yingle Liu; Ziyong Sun

    id:202002.0373/v1 Date: 2020-02-25 Source: Preprints.org

    Background: Coronavirus disease 2019 MESHD ( COVID-19 MESHD) is a new viral respiratory disease MESHD and whether pregnant women are at increased risk of infection is unknown. Viral pneumonia MESHD is an important indirect cause of maternal death MESHD. Little is known about the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy. Objective: To describe the clinical characteristics of COVID-19 MESHD in pregnancy and their newborn infant, and we sought to explored whether the SARS-CoV-2 can be intrauterine vertically transmitted. Study Design: The study was a case series study conducted in the obstetric ward of Tongji Hospital affiliated to Huazhong University of science and technology, Wuhan, China. Demographic, clinical, laboratory and radiological profiles of the SARS-CoV-2 infection MESHD case series. A systematic testing procedure for SARS-CoV-2 infection MESHD using oropharyngeal swab, placenta tissue, vaginal mucus, and breast milk of mothers. and oropharyngeal swab, umbilical cord blood, and serum of newborns was conducted. Results: We have conducted the most thorough virological assessment to date, and we include a longer clinical observation in mother-infant dyads during hospitalization. The clinical course and outcomes of three pregnant women who acquired SARS-CoV-2 infection MESHD late pregnancy are described in mother-infant dyads. Two had caesarean delivery in their third trimester. All patients showed an uneventful perinatal course, and a successful outcome. No infants became infected by vertical transmission or during delivery. Conclusion: No evidence to suggest the potential risk of intrauterine vertical transmission in the case series and further in-depth study is needed. Both the pregnancy woman and infant showed fewer adverse maternal and neonatal outcomes.

    Clinical characteristics of 25 death cases infected with COVID-19 MESHD pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China

    Authors: Xun Li; Luwen Wang; Shaonan Yan; Fan Yang; Longkui Xiang; Jiling Zhu; Bo Shen; Zuojiong Gong

    doi:10.1101/2020.02.19.20025239 Date: 2020-02-25 Source: medRxiv

    Summary Background The pneumonia MESHD caused by the 2019 novel coronavirus (SARS-CoV-2) is a highly infectious disease MESHD, which was occurred in Wuhan, Hubei Province, China in December 2019. As of February 13, 2020, a total of 59883 cases of COVID-19 MESHD in China have been confirmed and 1368 patients have died from the disease. However, the clinical characteristics of the dyed patients were still not clearly clarified. This study aims to summarize the clinical characteristics of death cases with COVID-19 MESHD and to identify critically ill patients of COVID-19 MESHD early and reduce their mortality. Methods The clinical records, laboratory findings and radiologic assessments included chest X-ray or computed tomography were extracted from electronic medical records of 25 died patients with COVID-19 MESHD in Renmin Hospital of Wuhan University from Jan 14 to Feb 13, 2020. Two experienced clinicians reviewed and abstracted the data. Findings The mean age of the dead was 71.48 years, the average course of the disease was 10.56 days, all patients eventually died of respiratory failure MESHD. All of those who died had underlying diseases, the most common of which was hypertension MESHD (16/25, 64%), followed by diabetes MESHD (10/25, 40%), heart diseases MESHD (8/25, 32%), kidney diseases MESHD (5/25, 20%), cerebral infarction MESHD (4/25, 16%), chronic obstructive pulmonary disease MESHD ( COPD MESHD, 2/25, 8%), malignant tumors MESHD (2/25, 8%) and acute pancreatitis MESHD (1/25, 4%). The most common organ damage outside the lungs was the heart, followed by kidney and liver. In the patients' last examination before death MESHD, white blood cell and neutrophil counts were elevated in 17 patients (17/25, 68%) and 18 patients (18/25, 72%), lymphocyte counts were decreased in 22 patients (22/25, 88%). Most patients' PCT HGNC, CRP HGNC and SAA levels were elevated, the percentages were 90.5% (19/21), 85% (19/20) and 100% (21/21) respectively. The levels of the last test of neutrophils (15/16, 93.8%), PCT HGNC (11/11, 100%), CRP HGNC (11/13, 84.6%), cTnI HGNC (8/9, 88.9%), D-Dimer (11/12, 91.6%) and LDH (9/9, 100%) were increased as compared to the first test, while the levels of lymphocytes were decreased (14/16, 87.5%). Interpretation The age and underlying diseases ( hypertension MESHD, diabetes MESHD, etc.) were the most important risk factors for death of COVID-19 MESHD pneumonia MESHD. Bacterial infections may play an important role in promoting the death of patients. Malnutrition MESHD was common to severe patients. Multiple organ dysfunction can be observed, the most common organ damage was lung, followed by heart, kidney and liver. The rising of neutrophils, SAA, PCT HGNC, CRP HGNC, cTnI HGNC, D-Dimer and LDH levels can be used as indicators of disease progression, as well as the decline of lymphocytes counts.

    A Peptide-based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus Disease 2019 ( COVID-19 MESHD)

    Authors: Xuefei Cai; Juan Chen; Jieli Hu; Quanxin Long; Haijun Deng; Kai Fan; Pu Liao; Beizhong Liu; Guicheng Wu; Yaokai Chen; Zhijie Li; Kun Wang; Xiaoli Zhang; Wenguang Tian; Jianglin Xiang; Hongxin Du; Jing Wang; Yuan Hu; Ni Tang; Yong Lin; Jihua Ren; Luyi Huang; Jie Wei; Chunyang Gan; Yanmeng Chen; Qingzhu Gao; Amei Chen; Changlong He; Daoxin Wang; Peng Hu; Fachun Zhou; Ailong Huang; Ping Liu; Deqiang Wang

    doi:10.1101/2020.02.22.20026617 Date: 2020-02-25 Source: medRxiv

    A respiratory illness has been spreading rapidly in China, since its outbreak in Wuhan city, Hubei province in December 2019. The illness was caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical manifestations related to SARS-CoV-2 infection MESHD ranged from no symptom to fatal pneumonia MESHD. World Health Organization (WHO) named the diseases associated with SARS-CoV-2 infection MESHD as COVID-19 MESHD. Real time RT-PCR is the only laboratory test available till now to confirm the infection. However, the accuracy of real time RT-PCR depends on many factors, including sampling location and of methods, quality of RNA extraction and training of operators etc. Variations in these factors might significantly lower the sensitivity of the detection. We developed a peptide-based luminescent immunoassay to detect IgG and IgM. Cut-off value of this assay was determined by the detection of 200 healthy sera and 167 sera from patients infected with other pathogens than SARS-CoV-2. To evaluate the performance of this assay, we detected IgG and IgM in the 276 sera from confirmed patients. The positive rate of IgG and IgM were 71.4% (197/276) and 57.2% (158/276) respectively. By combining with real time RT-PCR detection, this assay might help to enhance the accuracy of diagnosis of SARS-CoV-2 infection MESHD.

    Structural Genomics and Interactomics of 2019 Wuhan Novel Coronavirus, SARS-CoV-2, Indicate Evolutionary Conserved Functional Regions of Viral Proteins

    Authors: Hongzhu Cui; Ziyang Gao; Ming Liu; Senbao Lu; Winnie Mkandawire; Oleksandr Narykov; Suhas Srinivasan; Mo Sun; Dmitry Korkin

    id:10.20944/preprints202002.0372.v1 Date: 2020-02-25 Source: Preprints.org

    During its first month, the recently emerged 2019 Wuhan novel coronavirus (SARS-CoV-2) has already infected many thousands of people in mainland China and worldwide and took hundreds of lives. However, the swiftly spreading virus also caused an unprecedentedly rapid response from the research community facing the unknown health challenge of potentially enormous proportions. Unfortunately, the experimental research to understand the molecular mechanisms behind the viral infection MESHD and to design a vaccine or antivirals is costly and takes months to develop. To expedite the advancement of our knowledge we leverage the data about the related coronaviruses that is readily available in public databases, and integrate these data into a single computational pipeline. As a result, we provide a comprehensive structural genomics and interactomics road-maps of SARS-CoV-2 and use these information to infer the possible functional differences and similarities with the related SARS coronavirus. All data are made publicly available to the research community at http://korkinlab.org/wuhan .

    First cured patient with 2019 novel coronavirus in Changsha, China, a case report

    Authors: Jian Zhou; Di-xuan Jiang; Zi-qin Cao; Wanchun Wang; Kang Huang; Fang Zheng; Yuan-lin Xie; Zhi-guo Zhou

    doi:10.21203/rs.2.24731/v1 Date: 2020-02-25 Source: ResearchSquare

    Background: In December, 2019, the novel coronavirus (2019-nCoV) firstly occurred in Wuhan, Hubei Province, China. It spreads rapidly and many cases are identified in multiple countries, which pose a great threat to people's health. Here we report the first cured patient with 2019-nCoV infection MESHD in Changsha, China, and the symptoms, diagnosis, treatment and management of this patient are all described in the present study. Case presentation: A 57 year old woman developed cough and fever after returning from Wuhan to Changsha on January 9, 2020. She was tested positive for 2019-nCoV infection MESHD, which was supported by Chest CT. Lopinavir and ritonavir tablets and  interferon alfa-2b injection were used for treatment. A small dose of glucocorticoids were used in a short period to control the immune response in bilateral lung and this patient avoided the occurrence of cytokine storms. The clinical condition of this patient improved and negative result was obtained for 2019-nCoV assay on January 25, 2020. This patient was recovered and discharged on January 30, 2020. Conclusions: At present, many reports about 2019-nCoV infection MESHD focused on the epidemiological and clinical characteristics of this disease. This case described the symptoms, diagnosis, treatment and management of a cured patient with 2019-nCoV infection MESHD, which may provide information for the treatment of 2019-nCoV infection MESHD.

    Clinical features and laboratory inspection of novelcoronavirus pneumonia ( COVID-19 MESHD) in Xiangyang, Hubei

    Authors: Weiliang Cao

    doi:10.1101/2020.02.23.20026963 Date: 2020-02-25 Source: medRxiv

    Background: Since December 2019, a novel coronavirus pneumonia MESHD ( COVID-19 MESHD) rapidly spread in China, reached multiple continents currently.We aimed to reveal the infectious characteristics of COVID-19 MESHD that provide more information for the research of novel coronavirus. Methods: We performed a retrospective study on the clinical characteristics of 128 COVID-19 MESHD cases with laboratory-confirmed from Xiangyang No 1 Hospitalad during January 2020 to 16 February 2020. Results: Female patients account for 53.1%. The aged below 20 years that accounts for 1.6% of overall patients. The aged in 21~50, 51~65, over 66 years were accounts for 44.5%, 35.1%,18.8%, respectively. In the difference age spectrum, all severe groups compared with non-severe groups were difference significantly ( P < 0.01 ). Fever MESHD ( 89.8% ) and Cough ( 67.2% ) were common clinical symptoms. The rate of patients with sore throats (14.1%) was rare. The rate of chest computed tomography scan showing ground glass opacity in overall, non-severe, severe groups were 63.3%, 60.7%, 76.2%, respectively. White blood cell counts in the normal range of overall patients, but severe group patients were increased significantly ( P < 0.01). Lymphocytes of overall patients were decreased. Alanine transaminase (ALT) and aspartate transaminase ( AST HGNC) in the normal range of overall patients, but its were elevated in the severe group. Creatinine (CR) and blood urea nitrogen (BUN) of overall patients in the normal range. C-reactive protein HGNC ( CRP HGNC) level of all patients were increased markedly, but it in the severe group was significantly higher than that in the non-severe group ( P < 0.01 ). Conclusions: Our data provide more information that advanced age, lower lymphocytes levels at the diagnosed COVID-19 MESHD patients may be a risk factor for unfavourable prognosis. The white blood cells and C-reactive protein HGNC level elevated in severe COVID-19 MESHD patients may be accompanying bacterial infection MESHD. 2019-nCov may be carries a risk factor of impaired liver and kidney function MESHD.

    Mental health status and coping strategy of medical workers in China during The COVID-19 MESHD outbreak

    Authors: Chen Siyu; Min Xia; Weiping Wen; Liqian Cui; Weiqiang Yang; Shaokun Liu; Jiahua Fan Fan; Huijun Yue; Shangqing Tang; Bingjie Tang; Xiaoling Li; Lin Chen; Zili Qin; Kexing Lv; Xueqin Guo; Yu Lin; Yihui Wen; Wenxiang Gao; Ying Zheng; Wei Xu; Yun Li; Yang Xu; Li Ling; Wenbin Lei

    doi:10.1101/2020.02.23.20026872 Date: 2020-02-25 Source: medRxiv

    The authors have withdrawn their manuscript whilst they perform additional experiments to test some of their conclusions further. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.

    Characterizing the transmission and identifying the control strategy for COVID-19 MESHD through epidemiological modeling

    Authors: Ke K. Zhang; Linglin Xie; Lauren Lawless; Huijuan Zhou; Guannan Gao; Chengbin Xue

    doi:10.1101/2020.02.24.20026773 Date: 2020-02-25 Source: medRxiv

    The outbreak of the novel coronavirus disease MESHD, COVID-19 MESHD, originating from Wuhan, China in early December, has infected more than 70,000 people in China and other countries and has caused more than 2,000 deaths. As the disease continues to spread, the biomedical society urgently began identifying effective approaches to prevent further outbreaks. Through rigorous epidemiological analysis, we characterized the fast transmission of COVID-19 MESHD with a basic reproductive number 5.6 and proved a sole zoonotic source to originate in Wuhan. No changes in transmission have been noted across generations. By evaluating different control strategies through predictive modeling and Monte carlo simulations, a comprehensive quarantine in hospitals and quarantine stations has been found to be the most effective approach. Government action to immediately enforce this quarantine is highly recommended.

    Discovery of potential drugs for COVID-19 MESHD based on the connectivity map

    Authors: Zhonglin Li; Tao Bai; Ling Yang; Xiaohua Hou

    doi:10.21203/rs.2.24684/v1 Date: 2020-02-25 Source: ResearchSquare

    Background: Corona virus infective disease MESHD 19 ( COVID-19 MESHD) is the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and spreads very rapidly, which become a worldwide public healthy crisis. Until now, there is no effective antivirus drugs or vaccines specifically used for its treatment. So it is urgent to discover efficient therapeutic methods. The same as SARS-CoV, SARS-CoV-2 MESHD also invades organism by combining with Angiotensin-converting enzyme 2 HGNC ( ACE2 HGNC). Recently, there are reports about SARS-CoV-2 infected MESHD host not only through the respiratory tract, but also gastrointestinal tract. However, it is proved that ACE2 HGNC plays a key role in protecting subjects from lung injury MESHD and resisting the inflammation MESHD caused by intestinal epithelial damage. Interestingly, the expression of ACE2 HGNC protein is reduced after SARS-CoV infection MESHD. Methods: According to the dataset of genes co-expressed with ACE2 HGNC in the colonic epithelial cells, we established a protein-protein interaction (PPI) Network and selected hub genes from them. The cluster analysis was performed to find out the dense region of the PPI Network. Then, gene ontology (GO) and pathway enrichment analysis were performed to explore the main function of genes co-expressed with ACE2 HGNC. Finally, we predicted the potential drugs for the treatment of COVID-19 MESHD based on the connectivity map ( Cmap HGNC) . Results: We constructed a PPI network containing 125 hub genes of genes co-expressed with ACE2 HGNC in the colonic epithelial cells and obtained two modules through cluster analysis. The GO analysis and the KEGG pathway revealed these genes were aggregated in ribosome, exosomes, extracellular cellular components; structure constituent of ribosome, G-protein coupled receptor activity, MHC class I and II receptor activity biological processes; immune response, protein metabolism, signal transduction biological processes; and ribosome, graft-versus-host disease MESHD, viral myocarditis MESHD pathways. The result from Cmap HGNC indicated ikarugamycin, molsidomine had highly correlated scores with the query files. Conclusion: We found out that ikarugamycin and molsidomine were the potential drugs for the treatment of COVID-19 MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.